74 related articles for article (PubMed ID: 10346928)
1. Ligands for the tyrosine kinase p56lck SH2 domain: discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements.
Beaulieu PL; Cameron DR; Ferland JM; Gauthier J; Ghiro E; Gillard J; Gorys V; Poirier M; Rancourt J; Wernic D; Llinas-Brunet M; Betageri R; Cardozo M; Hickey ER; Ingraham R; Jakes S; Kabcenell A; Kirrane T; Lukas S; Patel U; Proudfoot J; Sharma R; Tong L; Moss N
J Med Chem; 1999 May; 42(10):1757-66. PubMed ID: 10346928
[TBL] [Abstract][Full Text] [Related]
2. Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56lck SH2 domain.
Llinaś-Brunet M; Beaulieu PL; Cameron DR; Ferland JM; Gauthier J; Ghiro E; Gillard J; Gorys V; Poirier M; Rancourt J; Wernic D; Betageri R; Cardozo M; Jakes S; Lukas S; Patel U; Proudfoot J; Moss N
J Med Chem; 1999 Feb; 42(4):722-9. PubMed ID: 10052978
[TBL] [Abstract][Full Text] [Related]
3. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
4. Lad, an adapter protein interacting with the SH2 domain of p56lck, is required for T cell activation.
Choi YB; Kim CK; Yun Y
J Immunol; 1999 Nov; 163(10):5242-9. PubMed ID: 10553045
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain.
Proudfoot JR; Betageri R; Cardozo M; Gilmore TA; Glynn S; Hickey ER; Jakes S; Kabcenell A; Kirrane TM; Tibolla AK; Lukas S; Patel UR; Sharma R; Yazdanian M; Moss N; Beaulieu PL; Cameron DR; Ferland JM; Gauthier J; Gillard J; Gorys V; Poirier M; Rancourt J; Wernic D; Llinas-Brunet M
J Med Chem; 2001 Jul; 44(15):2421-31. PubMed ID: 11448224
[TBL] [Abstract][Full Text] [Related]
6. The crystal structures of the SH2 domain of p56lck complexed with two phosphonopeptides suggest a gated peptide binding site.
Mikol V; Baumann G; Keller TH; Manning U; Zurini MG
J Mol Biol; 1995 Feb; 246(2):344-55. PubMed ID: 7532720
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution.
Tong L; Warren TC; King J; Betageri R; Rose J; Jakes S
J Mol Biol; 1996 Mar; 256(3):601-10. PubMed ID: 8604142
[TBL] [Abstract][Full Text] [Related]
8. Peptide ligands of pp60(c-src) SH2 domains: a thermodynamic and structural study.
Charifson PS; Shewchuk LM; Rocque W; Hummel CW; Jordan SR; Mohr C; Pacofsky GJ; Peel MR; Rodriguez M; Sternbach DD; Consler TG
Biochemistry; 1997 May; 36(21):6283-93. PubMed ID: 9174343
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis for regulation of Src by the docking protein p130Cas.
Nasertorabi F; Tars K; Becherer K; Kodandapani R; Liljas L; Vuori K; Ely KR
J Mol Recognit; 2006; 19(1):30-8. PubMed ID: 16245368
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand.
Plummer MS; Holland DR; Shahripour A; Lunney EA; Fergus JH; Marks JS; McConnell P; Mueller WT; Sawyer TK
J Med Chem; 1997 Nov; 40(23):3719-25. PubMed ID: 9371236
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
12. Potent dipeptide inhibitors of the pp60c-src SH2 domain.
Pacofsky GJ; Lackey K; Alligood KJ; Berman J; Charifson PS; Crosby RM; Dorsey GF; Feldman PL; Gilmer TM; Hummel CW; Jordan SR; Mohr C; Shewchuk LM; Sternbach DD; Rodriguez M
J Med Chem; 1998 May; 41(11):1894-908. PubMed ID: 9599239
[TBL] [Abstract][Full Text] [Related]
13. A quantum mechanical study on phosphotyrosyl peptide binding to the SH2 domain of p56lck tyrosine kinase with insights into the biochemistry of intracellular signal transduction events.
Pichierri F
Biophys Chem; 2004 May; 109(2):295-304. PubMed ID: 15110947
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs.
Romir J; Lilie H; Egerer-Sieber C; Bauer F; Sticht H; Muller YA
J Mol Biol; 2007 Feb; 365(5):1417-28. PubMed ID: 17118402
[TBL] [Abstract][Full Text] [Related]
15. Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.
Macias AT; Mia MY; Xia G; Hayashi J; MacKerell AD
J Chem Inf Model; 2005; 45(6):1759-66. PubMed ID: 16309282
[TBL] [Abstract][Full Text] [Related]
16. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase.
Bradshaw JM; Mitaxov V; Waksman G
J Mol Biol; 1999 Nov; 293(4):971-85. PubMed ID: 10543978
[TBL] [Abstract][Full Text] [Related]
17. Mutational investigation of the specificity determining region of the Src SH2 domain.
Bradshaw JM; Mitaxov V; Waksman G
J Mol Biol; 2000 Jun; 299(2):521-35. PubMed ID: 10860756
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of rosmarinic acid on Lck SH2 domain binding to a synthetic phosphopeptide.
Ahn SC; Oh WK; Kim BY; Kang DO; Kim MS; Heo GY; Ahn JS
Planta Med; 2003 Jul; 69(7):642-6. PubMed ID: 12898421
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A
J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484
[TBL] [Abstract][Full Text] [Related]
20. Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.
Wei CQ; Gao Y; Lee K; Guo R; Li B; Zhang M; Yang D; Burke TR
J Med Chem; 2003 Jan; 46(2):244-54. PubMed ID: 12519063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
